GlassScriptPhysician profile
Steven A Hardy
NPI 1851652036
$43,170.54
in general payments reported to CMS, 2019-2025
85 companies · $12K in 2025
The $12K reported for 2025 was more than what 90% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,252 · 2020: $1,973 · 2021: $3,833 · 2022: $4,987 · 2023: $5,750 · 2024: $11K · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $16K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Education: $77.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $16,366.15 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,681.25 |
| Education | $77.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $14,785.83 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $2,506.39 | 2019-2025 | |
| Ucb, INC. | $1,941.56 | 2019-2025 | Briviact, Rystiggo, Nayzilam |
| Emd Serono, INC. | $1,730.71 | 2019-2025 | Mavenclad |
| Celgene Corporation | $1,531.95 | 2021-2025 | Zeposia |
| Biogen, INC. | $1,331.07 | 2019-2025 | Tysabri, Vumerity, Skyclarys |
| Supernus Pharmaceuticals, INC. | $1,054.60 | 2019-2023 | |
| Genzyme Corporation | $810.65 | 2019-2025 | |
| Eisai INC. | $778.68 | 2019-2025 | |
| Pfizer INC. | $754.96 | 2019-2025 | |
| Lilly USA, LLC | $728.98 | 2019-2025 | Emgality, Kisunla, Reyvow |
| Lundbeck LLC | $692.14 | 2019-2025 | Vyepti, Rexulti |
| Teva Pharmaceuticals USA, INC. | $681.79 | 2019-2023 | Austedo, Austedo Xr |
| Genentech USA, INC. | $670.56 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Amgen INC. | $618.25 | 2019-2025 | Uplizna, Aimovig |
Show all 85 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Hardy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.